tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Apr;18(4):e13292.
doi: 10.1111/irv.13292. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Susana Monge[SUP] 1 2 [/SUP], James Humphreys[SUP] 3 [/SUP], Nathalie Nicolay[SUP] 4 [/SUP], Toon Braeye[SUP] 5 [/SUP], Izaak Van Evercooren[SUP] 5 [/SUP], Christian Holm Hansen[SUP] 6 [/SUP], Hanne-Dorthe Emborg[SUP] 6 [/SUP], Chiara Sacco[SUP] 7 8 [/SUP], Alberto Mateo-Urdiales[SUP] 7 [/SUP], Jesús Castilla[SUP] 9 10 [/SUP], Iván Martínez-Baz[SUP] 9 10 [/SUP], Brechje de Gier[SUP] 11 [/SUP], Susan Hahné[SUP] 11 [/SUP], Hinta Meijerink[SUP] 12 [/SUP], Anja Bråthen Kristoffersen[SUP] 12 [/SUP], Ausenda Machado[SUP] 13 [/SUP], Patricia Soares[SUP] 13 [/SUP], Anthony Nardone[SUP] 3 [/SUP], Sabrina Bacci[SUP] 4 [/SUP], Esther Kissling[SUP] 3 [/SUP], Baltazar Nunes[SUP] 3 [/SUP]; VEBIS‐EHR Working Group
Affiliations
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.
Keywords: COVID‐19; SARS‐CoV‐2; cohort design; electronic health records; hospitalisation; multicountry study; vaccine effectiveness.
. 2024 Apr;18(4):e13292.
doi: 10.1111/irv.13292. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Susana Monge[SUP] 1 2 [/SUP], James Humphreys[SUP] 3 [/SUP], Nathalie Nicolay[SUP] 4 [/SUP], Toon Braeye[SUP] 5 [/SUP], Izaak Van Evercooren[SUP] 5 [/SUP], Christian Holm Hansen[SUP] 6 [/SUP], Hanne-Dorthe Emborg[SUP] 6 [/SUP], Chiara Sacco[SUP] 7 8 [/SUP], Alberto Mateo-Urdiales[SUP] 7 [/SUP], Jesús Castilla[SUP] 9 10 [/SUP], Iván Martínez-Baz[SUP] 9 10 [/SUP], Brechje de Gier[SUP] 11 [/SUP], Susan Hahné[SUP] 11 [/SUP], Hinta Meijerink[SUP] 12 [/SUP], Anja Bråthen Kristoffersen[SUP] 12 [/SUP], Ausenda Machado[SUP] 13 [/SUP], Patricia Soares[SUP] 13 [/SUP], Anthony Nardone[SUP] 3 [/SUP], Sabrina Bacci[SUP] 4 [/SUP], Esther Kissling[SUP] 3 [/SUP], Baltazar Nunes[SUP] 3 [/SUP]; VEBIS‐EHR Working Group
Affiliations
- PMID: 38654485
- DOI: 10.1111/irv.13292
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.
Keywords: COVID‐19; SARS‐CoV‐2; cohort design; electronic health records; hospitalisation; multicountry study; vaccine effectiveness.